The Financial Burden of Localized and Metastatic Bladder Cancer
Bladder cancer treatment, especially for muscle-invasive and metastatic disease, is costly. Financial toxicity of bladder cancer is prevalent among younger patients and minorities. Research should prioritize the economic impact of new therapies to improve outcomes without increasing financial burdens on patients and health care systems.